Larner College of Medicine

Vikas Anathy

Professor, Pathology & Laboratory Medicine

Division Chief, Redox Biology and Pathology

PRONOUNS he/him

vikas.anathy@med.uvm.edu
(802) 656-0395
man smiling
vikas.anathy@med.uvm.edu
+18026560395
Linkedin
Pronouns he/him
Alma mater(s)
  • PhD, Biological Sciences, Madurai Kamaraj University, Madurai, India
  • MSc, Biotechnology, University of Mysore, Mysore, India
  • BSc, Biochemistry, Botany and Zoology, University of Mysore, Mysore, India
  • Postdoctoral Associate, University of Vermont College of Medicine, Burlington, Vermont
Affiliated Department(s)

Department of Pathology and Laboratory Medicine

Vermont Lung Center

UVM Cancer Center

Cellular, Molecular, and Biomedical Sciences Program

Vermont Immunology/Infectious Diseases

Areas of expertise

ER stress, UPR, influenza, respiratory diseases, pulmonary fibrosis, asthma.

BIO

Vikas Anathy, Ph.D. is a Professor and Division Chief of Redox Biology and Pathology in the Department of Pathology & Laboratory Medicine at the University of Vermont Larner College of Medicine, with over 22 years of experience in redox biology and lung pathobiology. He developed expertise in redox signaling and lung disease pathogenesis during postdoctoral training with Drs. Nick Heintz and Yvonne Janssen-Heininger at the University of Vermont. Dr. Anathy’s research focuses on endoplasmic reticulum (ER) stress responses and oxidative post-translational protein modifications that drive lung disease, including asthma, influenza-induced lung injury, and pulmonary fibrosis. His laboratory has developed novel lung epithelial–specific mouse models targeting apoptotic pathways, ER-resident redox enzymes, mitochondrial fission proteins, and key transcription factors regulating inflammation and remodeling. His group also advances translational strategies, including ER-targeted pharmacologic agents, protein- and antibody-based therapeutics, and enzymatic assays to interrogate ER oxidoreductase function in airway inflammation and acute lung injury. He has sustained extramural funding from the NIH, American Lung Association, American Thoracic Society, and Parker B. Francis Foundation, and maintains productive academic and industry collaborations. Dr. Anathy serves as a grant reviewer for the NIH, Consulting Editor for JCI Insight, Guest Editor for Frontiers in Physiology, and Co-Chair of the American Lung Association Emerging Pathogen Award panel. His scholarly output includes 67 PubMed-indexed publications, 3,494 citations (H-index 37), and five issued patents with translational potential, underscoring his commitment to advancing ER-redox biology and developing novel inhaled therapies for debilitating lung diseases.

Courses

  • MPBP 6300A- CMB grant proposal writing

Publications

Google Scholar Publications

Awards and Achievements

  • 2024 US Patent, 11883395; Method of Treating severe acute respiratory syndrome (SARS) infection by administering a protein disulfide isomerase (PDI) inhibitor, Issued May 14, 2020
  • 2018 US Patent, 9,907,828; Treatments of Oxidative Stress Conditions, Issued March 6, 2018
  • 2008 US Patent, 8,679,811 B2, Treatments Involving Glutaredoxins and Similar Agents, European patent P2167653 (A2), Int'l publication number WO 2008/154012 (A2)

Bio

Vikas Anathy, Ph.D. is a Professor and Division Chief of Redox Biology and Pathology in the Department of Pathology & Laboratory Medicine at the University of Vermont Larner College of Medicine, with over 22 years of experience in redox biology and lung pathobiology. He developed expertise in redox signaling and lung disease pathogenesis during postdoctoral training with Drs. Nick Heintz and Yvonne Janssen-Heininger at the University of Vermont. Dr. Anathy’s research focuses on endoplasmic reticulum (ER) stress responses and oxidative post-translational protein modifications that drive lung disease, including asthma, influenza-induced lung injury, and pulmonary fibrosis. His laboratory has developed novel lung epithelial–specific mouse models targeting apoptotic pathways, ER-resident redox enzymes, mitochondrial fission proteins, and key transcription factors regulating inflammation and remodeling. His group also advances translational strategies, including ER-targeted pharmacologic agents, protein- and antibody-based therapeutics, and enzymatic assays to interrogate ER oxidoreductase function in airway inflammation and acute lung injury. He has sustained extramural funding from the NIH, American Lung Association, American Thoracic Society, and Parker B. Francis Foundation, and maintains productive academic and industry collaborations. Dr. Anathy serves as a grant reviewer for the NIH, Consulting Editor for JCI Insight, Guest Editor for Frontiers in Physiology, and Co-Chair of the American Lung Association Emerging Pathogen Award panel. His scholarly output includes 67 PubMed-indexed publications, 3,494 citations (H-index 37), and five issued patents with translational potential, underscoring his commitment to advancing ER-redox biology and developing novel inhaled therapies for debilitating lung diseases.

Courses

  • MPBP 6300A- CMB grant proposal writing

Publications

Google Scholar Publications

Awards and Achievements

  • 2024 US Patent, 11883395; Method of Treating severe acute respiratory syndrome (SARS) infection by administering a protein disulfide isomerase (PDI) inhibitor, Issued May 14, 2020
  • 2018 US Patent, 9,907,828; Treatments of Oxidative Stress Conditions, Issued March 6, 2018
  • 2008 US Patent, 8,679,811 B2, Treatments Involving Glutaredoxins and Similar Agents, European patent P2167653 (A2), Int'l publication number WO 2008/154012 (A2)

Select Publications

  • The NADPH oxidase DUOX1 contributes to profibrotic macrophage activation and pulmonary fibrosis. Habibovic A, Lin MC, Morris CR, Schiffers C, da Cruz LC, van der Ploeg IS, Steinvoort F, Utermohlen O, Krönke M, Kumar A, Anathy V, Janssen-Heininger YMW, van der Vliet A. Am J Respir Cell Mol Biol. 2026 Feb 1;74(2):203-216. doi: 10.1165/rcmb.2024-0602OC. PMID: 40986746.
  • The protein disulfide isomerase A3 and osteopontin axis promotes influenza-induced lung remodelling. Kumar A, Mark ZF, Carbajal MP, DeLima DS, Chamberlain N, Walzer J, Ruban M, Chandrasekaran R, Daphtary N, Aliyeva M, Poynter ME, Janssen-Heininger YMW, Bates JH, Alcorn JF, Britto CJ, Dela Cruz CS, Jegga AG, Anathy V. Br J Pharmacol. 2024 Nov;181(22):4610-4627. doi: 10.1111/bph.16511. Epub 2024 Aug 8. PMID: 39118388.
  • Obesity exacerbates influenza-induced respiratory disease via the arachidonic acid-p38 MAPK pathway. Chandrasekaran R, Morris CR, Butzirus IM, Mark ZF, Kumar A, Souza De Lima D, Daphtary N, Aliyeva M, Poynter ME, Anathy V, Dixon AE. Front Pharmacol. 2023 Aug 23;14:1248873. doi: 10.3389/fphar.2023.1248873. eCollection 2023. PMID: 37680710.
  • Structural and functional fine mapping of cysteines in mammalian glutaredoxin reveal their differential oxidation susceptibility. Corteselli EM, Sharafi M, Hondal R, MacPherson M, White S, Lam YW, Gold C, Manuel AM, van der Vliet A, Schneebeli ST, Anathy V, Li J, Janssen-Heininger YMW. Nat Commun. 2023 Jul 28;14(1):4550. doi: 10.1038/s41467-023-39664-2. PMID: 3750736.
  • Inhibition of PDIA3 in club cells attenuates osteopontin production and lung fibrosis. Kumar A, Elko E, Bruno SR, Mark ZF, Chamberlain N, Mihavics BK, Chandrasekaran R, Walzer J, Ruban M, Gold C, Lam YW, Ghandikota S, Jegga AG, Gomez JL, Janssen-Heininger YM, Anathy V. Thorax. 2022 Jul;77(7):669-678. doi: 10.1136/thoraxjnl-2021-216882. Epub 2021 Aug 16. PMID: 34400514.
  • Reducing protein oxidation reverses lung fibrosis. Anathy V, Lahue KG, Chapman DG, Chia SB, Casey DT, Aboushousha R, van der Velden JLJ, Elko E, Hoffman SM, McMillan DH, Jones JT, Nolin JD, Abdalla S, Schneider R, Seward DJ, Roberson EC, Liptak MD, Cousins ME, Butnor KJ, Taatjes DJ, Budd RC, Irvin CG, Ho YS, Hakem R, Brown KK, Matsui R, Bachschmid MM, Gomez JL, Kaminski N, van der Vliet A, Janssen-Heininger YMW. Nat Med. 2018 Aug;24(8):1128-1135. doi: 10.1038/s41591-018-0090-y. Epub 2018 Jul 9. PMID: 29988126.